| 2027-08-01in 341 d | Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution | JAZZJazz Pharmaceuticals | Phase 4 | Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex | Active, not recruiting |
| 2027-08-01in 341 d | A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With Obesity | NVONovo Nordisk A/S | Phase 1 | Obesity | Recruiting |
| 2027-08-01in 341 d | Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: | SUPNSupernus Pharmaceuticals, Inc. | — | Parkinson's Disease | Recruiting |
| 2027-08-01in 341 d | Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) | VSTMVerastem, Inc. | Phase 2 | Ovarian Cancer | Not yet recruiting |
| 2027-08-02in 342 d | A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection | AZNAstraZeneca | Phase 3 | Lung Cancer | Active, not recruiting |
| 2027-08-02in 342 d | A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | PFEPfizer | Phase 1 | Melanoma | Recruiting |
| 2027-08-03in 343 d | NAI for Sepsis With Persistent Lymphopenia | IBRXImmunityBio, Inc. | Phase 2 | Sepsis, Septic Shock, Lymphopenia, Immunosuppression, Critical Illness | Not yet recruiting |
| 2027-08-03in 343 d | A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors | MRNAModernaTX, Inc. | Phase 1 | Solid Tumors | Recruiting |
| 2027-08-04in 344 d | A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors | AZNAstraZeneca | Phase 1/2 | Breast Cancer | Recruiting |
| 2027-08-04in 344 d | Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant | PFEPfizer | Phase 3 | Multiple Myeloma | Active, not recruiting |
| 2027-08-04in 344 d | A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1) | PFEPfizer | Phase 2 | Overweight | Recruiting |
| 2027-08-07in 347 d | Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab | AZNAstraZeneca | Phase 3 | Asthma | Recruiting |
| 2027-08-07in 347 d | A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation | BIIBBiogen | Phase 3 | Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation | Active, not recruiting |
| 2027-08-08in 348 d | Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD) | 4507.TShionogi | Phase 2 | Pompe Disease | Recruiting |
| 2027-08-09in 349 d | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy | ALNYAlnylam Pharmaceuticals | Phase 2 | Cerebral Amyloid Angiopathy | Recruiting |
| 2027-08-10in 350 d | A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury | LCTXLineage Cell Therapeutics, Inc. | Phase 1 | Spinal Cord Injury Cervical, Spinal Cord Injury Thoracic, Spinal Cord Injury, Acute, Spinal Cord Injury, Spinal Cord Injury, Chronic | Recruiting |
| 2027-08-10in 350 d | A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | REGNRegeneron Pharmaceuticals | Phase 1/2 | Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Recruiting |
| 2027-08-12in 352 d | A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine | PFEPfizer | Phase 1 | Migraine | Recruiting |
| 2027-08-13in 353 d | A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism | AZNAstraZeneca | Phase 3 | Primary Hyperaldosteronism | Recruiting |
| 2027-08-14in 354 d | A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease | PFEPfizer | Phase 1 | Hepatic Impairment, Healthy, Hepatic Insufficiency, Healthy Adults | Recruiting |
| 2027-08-15in 355 d | An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis | INCYIncyte Corporation | — | Atopic Dermatitis | Recruiting |
| 2027-08-15in 355 d | A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy | NVONovo Nordisk A/S | — | Obesity | Enrolling by invitation |
| 2027-08-16in 356 d | AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma | AZNAstraZeneca | Phase 1/2 | Multiple Myeloma | Recruiting |
| 2027-08-20in 360 d | A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) | ARWRArrowhead Pharmaceuticals | Phase 3 | Homozygous Familial Hypercholesterolemia | Active, not recruiting |
| 2027-08-20in 360 d | A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age | BNTXBioNTech SE | Phase 4 | COVID-19 | Recruiting |
| 2027-08-20in 360 d | A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea | REGNRegeneron Pharmaceuticals | Phase 2 | Functional Hypothalamic Amenorrhea (FHA) | Recruiting |
| 2027-08-25in 365 d | Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age | SNYSanofi | Phase 3 | Pneumococcal Disease | Active, not recruiting |
| 2027-08-26in 366 d | A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India | NVONovo Nordisk A/S | Phase 4 | Severe Postpartum Haemorrhage | Recruiting |
| 2027-08-27in 367 d | A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease | NVONovo Nordisk A/S | Phase 3 | Sickle Cell Disease | Recruiting |
| 2027-08-29in 369 d | Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab | INCYIncyte Corporation | Phase 2 | Hematologic Malignancies | Recruiting |
| 2027-08-30in 370 d | Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors | AZNAstraZeneca | Phase 1 | Lung Cancer | Recruiting |
| 2027-08-30in 370 d | Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease | AZNAstraZeneca | Phase 2 | APOL1-Mediated Kidney Disease | Recruiting |
| 2027-08-30in 370 d | A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab | AZNAstraZeneca | Phase 1 | Solid Tumors | Recruiting |
| 2027-08-30in 370 d | FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer | ONCYOncolytics Biotech | Phase 2 | Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer | Recruiting |
| 2027-08-30in 370 d | A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid Leukemia | PFEPfizer | — | Acute Myeloid Leukemia | Recruiting |
| 2027-08-30in 370 d | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. | RADXRadiopharm Theranostics, Ltd | Phase 1 | Colorectal Cancer | Not yet recruiting |
| 2027-08-30in 370 d | AETOS Shoulder System | SNNSmith & Nephew, Inc. | — | Osteoarthritis | Recruiting |
| 2027-08-30in 370 d | A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD) | SNYSanofi | Phase 4 | Graft-Versus-Host Disease | Not yet recruiting |
| Aug 2027≤ 371 d | A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. | AAPGAscentage Pharma Group Inc. | Phase 3 | Chronic Lymphocytic Leukemia | Recruiting |
| Aug 2027≤ 371 d | An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | ABBVAbbVie | Phase 3 | Chronic Lymphocytic Leukemia | Active, not recruiting |
| Aug 2027≤ 371 d | Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis | ABBVAbbVie | — | Ulcerative Colitis | Active, not recruiting |
| Aug 2027≤ 371 d | A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer | ABBVAbbVie | Phase 3 | Colorectal Cancer | Active, not recruiting |
| Aug 2027≤ 371 d | A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | ABBVAbbVie | Phase 3 | Ulcerative Colitis | Active, not recruiting |
| Aug 2027≤ 371 d | A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa | ABBVAbbVie | — | Alopecia Areata | Recruiting |
| Aug 2027≤ 371 d | A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections | ABBVAbbVie | Phase 1 | Healthy Volunteer | Active, not recruiting |
| Aug 2027≤ 371 d | ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response | ACADACADIA Pharmaceuticals Inc. | Phase 2 | Major Depressive Disorder | Recruiting |
| 2027-08-31in 371 d | A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM | ALNYAlnylam Pharmaceuticals | Phase 1/2 | Type 2 Diabetes | Active, not recruiting |
| Aug 2027≤ 371 d | AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus | ARTVArtiva Biotherapeutics, Inc. | Phase 1 | Lupus Nephritis | Active, not recruiting |
| Aug 2027≤ 371 d | A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia. | ASNDAscendis Pharma A/S | Phase 2 | Achondroplasia | Recruiting |
| Aug 2027≤ 371 d | A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide) | ASNDAscendis Pharma A/S | — | Hypoparathyroidism | Recruiting |
| Aug 2027≤ 371 d | A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism | ASNDAscendis Pharma A/S | Phase 3 | Hypoparathyroidism | Recruiting |
| Aug 2027≤ 371 d | Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer. | AVBPArriVent BioPharma, Inc. | Phase 1 | Ovarian Cancer | Recruiting |
| 2027-08-31in 371 d | Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users | AZNAstraZeneca | Phase 4 | Systemic Lupus Erythematosus | Recruiting |
| 2027-08-31in 371 d | Observational Study That Will Analyse the Spread and Stratification of Lung Cancer Risk Using Artificial Intelligence | AZNAstraZeneca | — | Lung Cancer | Not yet recruiting |
| Aug 2027≤ 371 d | WATCHMAN FLX Pro European Registry | BSXBoston Scientific Corporation | — | Atrial Fibrillation | Recruiting |
| 2027-08-31in 371 d | An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome | CANFCan-Fite BioPharma | Phase 2 | Lowe Syndrome | Not yet recruiting |
| Aug 2027≤ 371 d | Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma | CLLSCellectis S.A. | Phase 1/2 | Non-Hodgkin Lymphoma | Recruiting |
| Aug 2027≤ 371 d | A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP) | CLYMClimb Bio, Inc. | Phase 1/2 | Immune Thrombocytopenia (ITP), ITP, Biologics, Monoclonal, Anti-CD19 | Recruiting |
| Aug 2027≤ 371 d | Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen | CRNXCrinetics Pharmaceuticals Inc. | Phase 3 | Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum, Carcinoid Tumor of Cecum, Carcinoid Tumor of Liver, Carcinoid Tumor of Pancreas, Carcinoid Syndrome Diarrhea, Carcinoid Intestine Tumor | Recruiting |
| Aug 2027≤ 371 d | A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors | CRNXCrinetics Pharmaceuticals Inc. | Phase 1/2 | SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm | Recruiting |
| Aug 2027≤ 371 d | VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection | EBSEmergent BioSolutions | — | Complication of Smallpox Vaccination | Enrolling by invitation |
| Aug 2027≤ 371 d | A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1 | GILDGilead Sciences | Phase 2 | HIV | Recruiting |
| Aug 2027≤ 371 d | Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients With Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure | GNFT.PAGenfit | Phase 2 | Acute Decompensation of Liver Cirrhosis, Established Acute-on-Chronic Liver Failure | Not yet recruiting |
| Aug 2027≤ 371 d | REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome | IONSIonis Pharmaceuticals, Inc. | Phase 3 | Angelman Syndrome | Recruiting |
| Aug 2027≤ 371 d | Real World Registry for Use of the Ion Endoluminal System | ISRGIntuitive Surgical | — | Lung Cancer | Active, not recruiting |
| Aug 2027≤ 371 d | A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa | KPRXKiora Pharmaceuticals, Inc. | Phase 2 | Retinitis Pigmentosa | Recruiting |
| Aug 2027≤ 371 d | Phase 1/2 Study of KRRO-121 in Healthy Volunteers and Patients With UCD | KRROKorro Bio, Inc. | Phase 1/2 | Urea Cycle Disorders, Inborn, Urea Cycle Disorders, Ornithine Transcarbamylase (OTC) Deficiency, Arginase 1 Deficiency, NAGS Deficiency, Carbamylphosphate Synthetase I, Ornithine Transporter Mitochondrial 1, Argininosuccinate Synthase, Argininosuccinate Lyase Deficiency, N-acetyl Glutamate - Synthetase, Citrin Deficiency | Not yet recruiting |
| Aug 2027≤ 371 d | A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | LLYEli Lilly and Company | Phase 3 | Obesity | Active, not recruiting |
| Aug 2027≤ 371 d | A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | LLYEli Lilly and Company | Phase 3 | Obesity | Active, not recruiting |
| Aug 2027≤ 371 d | A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | LLYEli Lilly and Company | Phase 3 | Obesity | Active, not recruiting |
| Aug 2027≤ 371 d | A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis | LLYEli Lilly and Company | Phase 1 | ALS (Amyotrophic Lateral Sclerosis) | Recruiting |
| Aug 2027≤ 371 d | A Study of LY4302814 in Healthy Participants | LLYEli Lilly and Company | Phase 1 | Healthy | Recruiting |
| Aug 2027≤ 371 d | A Study of LY3439539 in Participants With Alzheimer's Disease | LLYEli Lilly and Company | Phase 1 | Alzheimer's Disease | Recruiting |
| Aug 2027≤ 371 d | A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity | LLYEli Lilly and Company | Phase 1 | Overweight | Recruiting |
| 2027-08-31in 371 d | Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide | MIRMMirum Pharmaceuticals, Inc. | Phase 2/3 | Chronic Hepatitis D | Recruiting |
| 2027-08-31in 371 d | Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia | MRNAModernaTX, Inc. | Phase 1/2 | Propionic Acidemia | Recruiting |
| Aug 2027≤ 371 d | Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia | NBIXNeurocrine Biosciences | Phase 2 | Schizophrenia | Recruiting |
| Aug 2027≤ 371 d | A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis | OGNOrganon and Co | Phase 3 | Atopic Dermatitis | Active, not recruiting |
| Aug 2027≤ 371 d | A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU) | PVLAPalvella Therapeutics, Inc. | Phase 2 | Angiokeratomas | Recruiting |
| Aug 2027≤ 371 d | Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA | RAREUltragenyx Pharmaceutical Inc | Phase 3 | Mucopolysaccharidosis IIIA, MPS IIIA, Sanfilippo Syndrome, Sanfilippo A | Enrolling by invitation |
| Aug 2027≤ 371 d | A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD | RAREUltragenyx Pharmaceutical Inc | Phase 3 | Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) | Active, not recruiting |
| 2027-08-31in 371 d | Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy | REGNRegeneron Pharmaceuticals | Phase 1 | Food Allergy | Active, not recruiting |
| Aug 2027≤ 371 d | RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures | SUPNSupernus Pharmaceuticals, Inc. | Phase 2 | Epilepsy and Seizure Disorders | Recruiting |
| Aug 2027≤ 371 d | Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM | TNYATenaya Therapeutics | Phase 1/2 | Hypertrophic Cardiomyopathy | Recruiting |
| Aug 2027≤ 371 d | A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment | TVTXTravere Therapeutics, Inc. | Phase 3 | Homocystinuria | Recruiting |
| Aug 2027≤ 371 d | Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3) | VRCAVerrica Pharmaceuticals Inc. | Phase 3 | Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts | Not yet recruiting |
| Aug 2027≤ 371 d | Affixus Natural Nail System Humeral Nail PMCF | ZBHZimmer Biomet | — | Humeral Fractures, Proximal, Humeral Fractures | Active, not recruiting |
